search
Back to results

iFuse Implant System® Minimally Invasive Arthrodesis (iMIA)

Primary Purpose

Sacroiliac Joint Pain

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
iFuse Implant System
Conservative Management
Sponsored by
SI-BONE, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sacroiliac Joint Pain

Eligibility Criteria

21 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age 21-70 at time of screening
  2. Patient has lower back pain for >6 months or >18 months for pregnancy induced lower back pain
  3. Diagnosis of the SI joint as the primary lower back pain generator based on ALL of the following: a. Patient has pain at or close to the posterior superior iliac spine (PSIS) with possible radiation into buttocks, posterior thigh or groin and can point with a single finger to the location of pain (Fortin Finger Test), and b. Patient has at least 3 of 5 physical examination maneuvers specific for SI joint pain, and c. Patient has improvement in lower back pain NRS of at least 50% of the pre injection NRS score after fluoroscopic controlled injection of local anesthetic into affected SI joint(s) (including previous documented test <6 months ago)
  4. Baseline Oswestry Disability Index (ODI) score of at least 30%
  5. Baseline lower back pain score of at least 50 on 0-100 point VAS
  6. Patient has signed study-specific informed consent form
  7. Patient has the necessary mental capacity to participate and is physically able to comply with study protocol requirements

Exclusion Criteria:

  1. Severe lower back pain due to other causes, such as lumbar disc degeneration, lumbar disc herniation, lumbar spondylolisthesis, lumbar spinal stenosis, lumbar facet degeneration, and lumbar vertebral body fracture
  2. Sacroiliac pathology caused by auto-immune disease (e.g. ankylosing spondylitis) and/or neoplasia (e.g. benign or malignant tumor) and/or crystal arthropathy
  3. History of recent (<1 year) fracture of the pelvis with documented malunion, non-union of sacrum or ilium or any type of internal fixation of the pelvic ring.
  4. Spine surgery during the past 12 months.
  5. Previously diagnosed or suspected osteoporosis (defined as prior T-score <-2.5 or history of osteoporotic fracture)
  6. Documented osteomalacia or other metabolic bone disease
  7. Any condition or anatomy that makes treatment with the iFuse Implant System infeasible
  8. Known allergy to titanium or titanium alloys
  9. Use of medications known to have detrimental effects on bone quality and soft-tissue healing
  10. Prominent neurologic condition that would interfere with physical therapy
  11. Current systemic infection or local infection at the SI joint
  12. Currently pregnant or planning pregnancy in the next year
  13. Known or suspected drug or alcohol abuse
  14. Diagnosed psychiatric disease (e.g., schizophrenia, major depression, personality disorders) that could interfere with study participation
  15. Patient is participating in an investigational study or has been involved in an investigational study within 3 months of surgery

Sites / Locations

  • OLV Ziekenhuis Aalst
  • La Clinique de l'Espérance
  • Charité - Universitätsmedizin Berlin
  • Universitätsklinikum Bonn
  • Praxisgemeinschaft "Leben in Bewegung"
  • Istituto Ortopedico Rizzoli
  • Ospedale Civile Di Legnano
  • IRCCS Policlinico San Matteo
  • Aleris Specialistvård Ängelholm, Ortopedkliniken

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

iFuse Implant System

conservative management

Arm Description

Surgical placement of iFuse implants in the affected SI joint

Medications, physical therapy, information

Outcomes

Primary Outcome Measures

The change in lower back pain as rated by the study subject using a 0-100 visual analog scale (VAS) at 6 months after initiation of treatment

Secondary Outcome Measures

Change from baseline in lower back pain (VAS)
Change from baseline in leg pain (VAS
Change in disability due to back pain (ODI
Change in quality of life (EQ-5D
Change in ambulatory and work status
Change in depression score (Zung Depression Scale
Change in objective functional test (ASLR
Change in walking distance
Patient satisfaction and self-rating of disease state
Serious adverse events
Device breakage, loosening and migration

Full Information

First Posted
November 30, 2012
Last Updated
September 30, 2017
Sponsor
SI-BONE, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01741025
Brief Title
iFuse Implant System® Minimally Invasive Arthrodesis
Acronym
iMIA
Official Title
A Multicenter Randomized Controlled Post-market Clinical Follow-up Trial Comparing the Effectiveness and Safety of the iFuse Implant System® Versus Conservative Management for Patients With Chronic, Disabling SI Joint Pain.
Study Type
Interventional

2. Study Status

Record Verification Date
September 2017
Overall Recruitment Status
Completed
Study Start Date
June 2013 (undefined)
Primary Completion Date
December 15, 2015 (Actual)
Study Completion Date
September 24, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
SI-BONE, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to compare outcomes when patients with chronic sacroiliac joint pain undergo either SI joint fusion with the iFuse Implant System or undergo conservative management of the SI joint
Detailed Description
This study is a multicenter randomized controlled, post-market clinical follow-up clinical trial of the iFuse Implant System for SI joint fusion vs. conservative management. Subjects assigned to conservative management may cross over to iFuse after a minimum of 6 months of conservative treatment. Conservative management does not include interventional procedures such as prolotherapy, steroid injections and/or RF ablation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sacroiliac Joint Pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
103 (Actual)

8. Arms, Groups, and Interventions

Arm Title
iFuse Implant System
Arm Type
Experimental
Arm Description
Surgical placement of iFuse implants in the affected SI joint
Arm Title
conservative management
Arm Type
Active Comparator
Arm Description
Medications, physical therapy, information
Intervention Type
Device
Intervention Name(s)
iFuse Implant System
Intervention Description
Placement of iFuse implant system via surgery
Intervention Type
Other
Intervention Name(s)
Conservative Management
Intervention Description
Medications for pain, physical therapy, cognitive behavour therapy
Primary Outcome Measure Information:
Title
The change in lower back pain as rated by the study subject using a 0-100 visual analog scale (VAS) at 6 months after initiation of treatment
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Change from baseline in lower back pain (VAS)
Time Frame
1, 3, 12 and 24 months
Title
Change from baseline in leg pain (VAS
Time Frame
1, 3, 6, 12 and 24 months
Title
Change in disability due to back pain (ODI
Time Frame
3, 6, 12 and 24 months
Title
Change in quality of life (EQ-5D
Time Frame
3, 6, 12 and 24 months
Title
Change in ambulatory and work status
Time Frame
1, 3, 6, 12 and 24 months
Title
Change in depression score (Zung Depression Scale
Time Frame
3, 6, 12 and 24 months
Title
Change in objective functional test (ASLR
Time Frame
3, 6, 12 and 24 months
Title
Change in walking distance
Time Frame
3, 6, 12 and 24 months
Title
Patient satisfaction and self-rating of disease state
Time Frame
3, 6, 12 and 24 months
Title
Serious adverse events
Time Frame
during 24 months
Title
Device breakage, loosening and migration
Time Frame
12 months
Other Pre-specified Outcome Measures:
Title
Surgical re-interventions of target SI joint(s)
Time Frame
over 24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 21-70 at time of screening Patient has lower back pain for >6 months or >18 months for pregnancy induced lower back pain Diagnosis of the SI joint as the primary lower back pain generator based on ALL of the following: a. Patient has pain at or close to the posterior superior iliac spine (PSIS) with possible radiation into buttocks, posterior thigh or groin and can point with a single finger to the location of pain (Fortin Finger Test), and b. Patient has at least 3 of 5 physical examination maneuvers specific for SI joint pain, and c. Patient has improvement in lower back pain NRS of at least 50% of the pre injection NRS score after fluoroscopic controlled injection of local anesthetic into affected SI joint(s) (including previous documented test <6 months ago) Baseline Oswestry Disability Index (ODI) score of at least 30% Baseline lower back pain score of at least 50 on 0-100 point VAS Patient has signed study-specific informed consent form Patient has the necessary mental capacity to participate and is physically able to comply with study protocol requirements Exclusion Criteria: Severe lower back pain due to other causes, such as lumbar disc degeneration, lumbar disc herniation, lumbar spondylolisthesis, lumbar spinal stenosis, lumbar facet degeneration, and lumbar vertebral body fracture Sacroiliac pathology caused by auto-immune disease (e.g. ankylosing spondylitis) and/or neoplasia (e.g. benign or malignant tumor) and/or crystal arthropathy History of recent (<1 year) fracture of the pelvis with documented malunion, non-union of sacrum or ilium or any type of internal fixation of the pelvic ring. Spine surgery during the past 12 months. Previously diagnosed or suspected osteoporosis (defined as prior T-score <-2.5 or history of osteoporotic fracture) Documented osteomalacia or other metabolic bone disease Any condition or anatomy that makes treatment with the iFuse Implant System infeasible Known allergy to titanium or titanium alloys Use of medications known to have detrimental effects on bone quality and soft-tissue healing Prominent neurologic condition that would interfere with physical therapy Current systemic infection or local infection at the SI joint Currently pregnant or planning pregnancy in the next year Known or suspected drug or alcohol abuse Diagnosed psychiatric disease (e.g., schizophrenia, major depression, personality disorders) that could interfere with study participation Patient is participating in an investigational study or has been involved in an investigational study within 3 months of surgery
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Daniel Cher
Organizational Affiliation
SI-BONE, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
OLV Ziekenhuis Aalst
City
Aalst
ZIP/Postal Code
9300
Country
Belgium
Facility Name
La Clinique de l'Espérance
City
Montegnée
ZIP/Postal Code
4420
Country
Belgium
Facility Name
Charité - Universitätsmedizin Berlin
City
Berlin
ZIP/Postal Code
12200
Country
Germany
Facility Name
Universitätsklinikum Bonn
City
Bonn
ZIP/Postal Code
53127
Country
Germany
Facility Name
Praxisgemeinschaft "Leben in Bewegung"
City
Hilden
ZIP/Postal Code
40721
Country
Germany
Facility Name
Istituto Ortopedico Rizzoli
City
Bologna
ZIP/Postal Code
40136
Country
Italy
Facility Name
Ospedale Civile Di Legnano
City
Legnano
ZIP/Postal Code
20025
Country
Italy
Facility Name
IRCCS Policlinico San Matteo
City
Pavia
ZIP/Postal Code
27100
Country
Italy
Facility Name
Aleris Specialistvård Ängelholm, Ortopedkliniken
City
Ängelholm
ZIP/Postal Code
26262
Country
Sweden

12. IPD Sharing Statement

Citations:
PubMed Identifier
28934785
Citation
Dengler JD, Kools D, Pflugmacher R, Gasbarrini A, Prestamburgo D, Gaetani P, van Eeckhoven E, Cher D, Sturesson B. 1-Year Results of a Randomized Controlled Trial of Conservative Management vs. Minimally Invasive Surgical Treatment for Sacroiliac Joint Pain. Pain Physician. 2017 Sep;20(6):537-550.
Results Reference
derived
PubMed Identifier
27629371
Citation
Dengler J, Sturesson B, Kools D, Prestamburgo D, Cher D, van Eeckhoven E, Erk E, Pflugmacher R, Vajkoczy P; the iMIA study group. Referred leg pain originating from the sacroiliac joint: 6-month outcomes from the prospective randomized controlled iMIA trial. Acta Neurochir (Wien). 2016 Nov;158(11):2219-2224. doi: 10.1007/s00701-016-2953-7. Epub 2016 Sep 15.
Results Reference
derived
PubMed Identifier
27179664
Citation
Sturesson B, Kools D, Pflugmacher R, Gasbarrini A, Prestamburgo D, Dengler J. Six-month outcomes from a randomized controlled trial of minimally invasive SI joint fusion with triangular titanium implants vs conservative management. Eur Spine J. 2017 Mar;26(3):708-719. doi: 10.1007/s00586-016-4599-9. Epub 2016 May 14.
Results Reference
derived
Available IPD and Supporting Information:
Available IPD/Information Type
publication 6 month results
Available IPD/Information URL
https://www.ncbi.nlm.nih.gov/pubmed/27179664
Available IPD/Information Type
publication 6 month results
Available IPD/Information URL
https://www.ncbi.nlm.nih.gov/pubmed/27629371

Learn more about this trial

iFuse Implant System® Minimally Invasive Arthrodesis

We'll reach out to this number within 24 hrs